Serie de casos de pacientes con hepatocarcinoma tratados con sorafenib como terapia puente a quimioembolización y finalmente como paliativo

Introduction

There are patients with hepatocellular carcinoma who are candidates for chemoembolisation that face long delays due to waiting for the imaging assessment of that procedure by the radiologist.

Objective

To describe the results of a series of patients who received sorafenib as a bridge therapy during the time of deferral for chemoembolisation.

Material and methods

An analysis was made of the records of patients with hepatocellular carcinoma that were assessed in the digestive tract neoplasms functional unit (UFNAD) from August 2015 to February 2016, in order to detect those that had been treated with sorafenib as a bridge to chemoembolisation.

Results

A total of 14 patients with hepatocellular carcinoma were evaluated in the UFNAD in this period, with 9 of them receiving sorafenib as bridge therapy. It was used as initial therapy in 7, after radiofrequency in 2. None of them received the local therapy for which the sorafenib was planned as bridge, and all for reasons other than progression.

Conclusion

If chemoembolisation has to delayed, it is feasible to use sorafenib as a bridging therapy, which can also serve to avoid delay in palliative therapy if the patient turns out not to be a candidate for local therapy.